Related Experiment Video

Updated: Mar 24, 2026

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

2.1K

Vaccines for the prevention against the threat of MERS-CoV

Lanying Du1, Wanbo Tai1,2, Yusen Zhou2

  • 1a Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY , USA.

Expert Review of Vaccines
|March 18, 2016
PubMed

Insights

Middle East respiratory syndrome (MERS) coronavirus is a high-mortality pathogen with no available vaccines. This review details MERS immune responses, vaccine criteria, and animal models to guide effective MERS vaccine development.

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), identified in 2012, is a Category C Priority Pathogen.
  • MERS-CoV infection exhibits high mortality and potential for human-to-human transmission.
  • Currently, no vaccines are available for human use against MERS-CoV.

Purpose of the Study:

  • To review immune responses elicited by MERS-CoV infection.
  • To outline essential criteria for MERS vaccine development.
  • To present small animal models for evaluating MERS vaccine efficacy.

Main Methods:

  • Literature review of MERS-CoV immunology and vaccine research.
  • Analysis of current MERS vaccine development strategies.
  • Evaluation of small animal models for preclinical MERS vaccine testing.

Main Results:

  • Summary of immune responses to MERS-CoV infection.
  • Discussion of key criteria for safe and effective MERS vaccines.
  • Overview of existing MERS vaccine candidates, including their applications and limitations.

Conclusions:

  • The review provides guidelines for developing effective and safe MERS vaccines.
  • Understanding immune responses and utilizing appropriate models are crucial for MERS vaccine advancement.
  • This work contributes to biodefense strategies against MERS-CoV.
Keywords:
Animal modelsMERSMERS-CoVimmune responsesneutralizing antibodyprotectionspike proteinvaccines

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-208:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.4K
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.5K

Related Concept Videos

Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
29
Vaccinations01:51

Vaccinations

Overview
53.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
30
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
30
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
4.8K